Corvus Pharmaceuticals Inc (CRVS)
5.77
-0.26
(-4.31%)
USD |
NASDAQ |
Jan 07, 15:28
Corvus Pharmaceuticals SG&A Expense (Quarterly): 2.033M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.975M |
| Sarepta Therapeutics Inc | 128.20M |
| Cara Therapeutics Inc | 6.402M |
| Atara Biotherapeutics Inc | 10.42M |
| Clearside Biomedical Inc | 2.844M |